stojdllab

[stojdllab]

An integrated model of cellular states, tissue plasticity and genetics provides comprehensive insights for brain cancer immunotherapy

http://bit.ly/2MeTVir

Image credit: Neftel et al. 2019

[stojdllab]

After PD-1 blockade, the T cells that expand don't seem to be pre-existing tumor-infiltrating T lymphocytes but instead T cells with novel reactivities that weren't previously present in the tumour

https://go.nature.com/2BdZw2p

Image credit: Yost et al. 2019

[stojdllab]

Monitoring local vs. peripheral changes in cellular immunomes during cancer immunotherapy

Interesting study from Frontiers in Immunology & Duke University getting their biomarker immune analysis ready to go for an oncolytic virus trial for recurrent glioblastoma.

http://bit.ly/35AXrLI

[stojdllab]

T-Scan: a genome-wide, high-throughput method for the systematic discovery of T cell epitopes

http://bit.ly/2VEVyZU

Image credit: Kula et al. 2019

[stojdllab]

The compartmental distribution of PD-L1 might dictate whether we should block it, knock it down or inhibit it during cancer immunotherapy

http://bit.ly/2ONuTZM Image credit: Wu et al. 2019

[stojdllab]

Physically crosslinked injectable hydrogels for the long-term delivery of oncolytic viruses for cancer therapy

https://rsc.li/2Mpfmfz

Image credit: Le et al. 2019

[stojdllab]

Fascinating paper describes how blocking tumour IFNg signalling can actually stimulate exhausted T cells to produce more IFNg & reject tumours with favorable antigenicity profiles

http://bit.ly/2AVuTia

Image: Benci et al. 2019 

[stojdllab]

Targeting cancer stem cells and their supportive niche using oncolytic virus immunotherapy

http://bit.ly/2p3HA7A

Image credit: Crupi et al. 2019

[stojdllab]

Cool new technology: empty-loadable tetramers that convert into antigen-specific tetramers by a single-step peptide addition & can identify neoantigen -specific T cells for cancer immunotherapy

http://bit.ly/2VmAkji Image: Saini et al. 2019

[stojdllab]

Interesting review on rationally combining immunotherapy with synergistic radiotherapy to mobilise anti-cancer immunity

http://bit.ly/30UNpBI Image credit: Herrera et al. 2019

[stojdllab]

Chemo-radiotherapy can upregulate PD-L1 expression in tumour samples, providing a clinical rationale for subsequent immune checkpoint inhibition

https://go.nature.com/33A11oG

Image credit: Yoneda et al. 2019

[stojdllab]

Gene panels designed to estimate tumour mutation burden should move away from 'correlation' to focus on 'accuracy' to avoid overestimation

http://bit.ly/31Dd16H

Image credit: Wu et al. 2019

[stojdllab]

Alternative mRNA splicing alters the proteomic diversity of many cancers and may offer a broader target space for cancer immunotherapy

https://go.nature.com/2Kw1LDC

Image credit: Frankiw et al. 2019 

[stojdllab]

Immune conversion of the tumour microenvironment by oncolytic viruses

http://bit.ly/2KJahxU

Image credit: Marchini et al. 2019

[stojdllab]

Our newest publication is out!

Co-delivering mRNA wrapped in a new lipopolyplex formulation induces a strong anti-tumour immune response upon intravenous administration

http://bit.ly/2KGrSGM Image credit: Guevara et al. 2019

[stojdllab]

Mutation-derived neoantigens for cancer immunotherapy

http://bit.ly/2YFmzk9

Image credit: Castle et al. 2019

[stojdllab]

Diverse cancer immunotherapies can effectively treat syngeneic brainstem tumours in the absence of overt toxicity

http://bit.ly/2yHh5q8

Image credit: Schuelke et al. 2019